Date:12/6/2010

ctor of Konbit Sante, long-time partner of the Justinian University Hospital.  "Up to 80 percent of stricken patients should be able to be rehydrated with ORS, but of the hundreds of patients in Cap-Haitien coming to the cholera treatment centers each day, the vast majority are so dehydrated by the time they arrive that they require I.V. hydration to survive.  CSL Behring's donation of I.V. products is truly life-saving and will be deployed where it is most needed in the area."

In the months following the 7.0-magnitude earthquake that struck Haiti's capital, Direct Relief has delivered emergency medical assistance valued at more than $54 million (wholesale) – over 643 tons – to more than 100 healthcare providers. Having worked in Haiti since 1964, Direct Relief had strong relationships with the country's largest hospitals and clinics, allowing the organization to rapidly deploy resources to where they were needed most.

About Direct Relief InternationalFounded in 1948, Direct Relief is a Santa Barbara, California-based nonprofit organization focused on improving quality of life by bringing critically needed medicines and supplies to local healthcare providers worldwide. Direct Relief has provided more than $1 billion in privately funded humanitarian aid since 2000, including more than $225 million in assistance in the United States. It has earned a fundraising efficiency score of 100 percent for the eighth year from Forbes in 2010, and is ranked by the Chronicle of Philanthropy as California's largest international nonprofit organization based on private support. For more information, please visit www.DirectRelief.org.

About CSL BehringCSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-deri
'/>"/>

SOURCE Direct Relief International Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
2. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
3. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
4. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
5. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
6. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
7. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
8. China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program
9. The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas
10. CSA Medical Appoints William H. Floyd President and CEO
11. Cayenne Medical, Inc. Reaches 50,000 Implant Milestone